The role of alpha 1-blockers in combination therapy for hypertension

R M Zusman1

  • 1Division of Hypertension and Vascular Medicine, Massachusetts General Hospital, Boston 02114, USA.

Insights

For many patients, hypertension (high blood pressure) requires more than one medication. Adding an alpha1-blocker effectively improves blood pressure control and offers additional health benefits.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Antihypertensive monotherapy achieves adequate blood pressure control in less than 50% of patients, particularly those with stage 2-3 hypertension.
  • Hypertension frequently coexists with other conditions like type 2 diabetes mellitus and benign prostatic hyperplasia.

Purpose of the Study:

  • To review clinical studies on the efficacy and tolerability of alpha1-blocker add-on therapy for inadequately controlled hypertension.
  • To explore the additional therapeutic benefits of alpha1-blockers beyond blood pressure management.

Main Methods:

  • Review of clinical studies evaluating alpha1-blockers (doxazosin, terazosin, prazosin) as add-on therapy.
  • Analysis of effects on blood pressure control, tolerability, serum lipid profile, and coexisting conditions.

Main Results:

  • Add-on therapy with alpha1-blockers is effective and well-tolerated for improving blood pressure control in patients with resistant hypertension.
  • Alpha1-blockers demonstrate a small positive effect on serum lipid profiles.
  • Favorable or benign effects were observed in patients with coexisting type 2 diabetes mellitus and benign prostatic hyperplasia.

Conclusions:

  • Alpha1-blocker add-on therapy is a valuable strategy for achieving blood pressure control in patients with inadequately managed hypertension.
  • Alpha1-blockers offer multifaceted therapeutic advantages, including lipid profile improvement and beneficial effects on common comorbidities.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...